Precision HD trial update

The exciting trials Precision HD 1 and 2, continue to enroll participants. Wave Life Sciences expect to share the first results by the end of 2019. In the Huntingtin lowering trials, Wave […]

Accelerated evaluation of drug

The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that may significantly improve patients’ quality of life and granted Priority […]

Amazing news – drug seems to improve symptoms

Yesterday Ionis Pharmaceutical presented new data from their Huntingtin lowering trial, IONIS-HTTRx. The data demonstrates a relationship between reduction of the disease-causing  Huntingtin protein and improved symptoms for people with […]

Update message from the Roche team

On her way to board a flight to Los Angeles Mai-Lise Nguyen, Patient Partnership Director at Roche, sent an update letter to all of us who are impatiently waiting for […]

Wave partners with Takeda – HD research strengthened

The biotechnology company Wave Life Sciences strengthens their efforts in Huntington’s disease. In February they announced  their collaboration with Takeda, a Japanese pharmaceutical company with long and solid traditions.  The […]

Milano taking HD needs into universal design

On June 29th the the HD Associations AICH Milano and Huntington Onlus opened a very exciting and innovative Exhibition at the famous art Exhibition venue Triennale Design Museum in Milano.  “Second […]

General Assembly Minutes

General Assembly Minutes General Assembly 2025 Find here the minutes form our General Assembly meeting online, 2025 Minutes of the General Assembly